NHS England & Vertex reach deal for sickle cell gene therapy Casgevy, making it available at an undisclosed reduced price ...

AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed ...

South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...

Novartis said Friday that last year was one of its 'strongest' financial performances in its history following a multiyear ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...

Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...

A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...

Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in 2023.

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...